Alterity Therapeutics Ltd has released a press release.
Alterity Presents Encouraging New Phase 2 Data in MSA
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
In the deck
Story so far
Earlier from Alterity Therapeutics
- Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
- Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
- Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
- Alterity Completes Last Patient Visit in Open-Label Trial
- Alterity raises A$40m to Advance ATH434 Development in MSA
Later from Alterity Therapeutics
- Alterity Phase 2 Presentation at AAN 2025
- Options Prospectus
- Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
- Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
- Alterity Granted U.S. FDA Fast Track Designation for ATH434
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics